SynthesisFrontiers in cellular and infection microbiology2025
Colistin-based combination therapy versus monotherapy for carbapenem-resistant gram-negative bacterial infections: a systematic review and meta-analysis.
Synthesis in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Colistin therapy and survival outcomes in neonatal carbapenem-resistant gram-negative sepsis.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Synergistic strategies to rescue the last-resort antibiotic colistin.Archives of microbiology · 2026Review
- Predictors of clinical outcomes in Chinese patients with carbapenem-resistant Gram-negative bacterial infections receiving colistimethate sodium: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The objective of this study was to summarize available data on colistin (COL) combination therapy or monotherapy for carbapenem-resistant gram-negative bacteria (CR-GNB). Methods: Two reviewers independently evaluated and extracted data from PubMed, Embase, and Cochrane Library from inception to January 31, 2025, for studies comparing COL combination therapy with monotherapy in patients with CR-GNB infections. The primary outcome was all-cause mortality, and secondary outcomes included microbiological eradication rate, clinical improvement rate, length of stay (LOS), nephrotoxicity, and neurotoxicity. Differences for dichotomous outcomes were expressed as risk ratios (RRs) with 95% confidence intervals (CIs), whereas those for continuous outcomes were expressed as mean differences (MDs) with 95% confidence intervals (CIs). The risk of bias was assessed with the Cochrane tools. Certainty of evidence was assessed using GRADE. This systematic review was registered with PROSPERO (CRD42025636727). Results: A total of 26 eligible studies were included. Moderate-quality evidence indicates that compared with COL monotherapy, COL combination therapy significantly increased microbial eradication rate (RR 1.07, 95% CI 1.00-1.13, Conclusion: Moderate-quality evidence suggests that COL combination therapy improved microbiological eradication rates in CRAB infections compared to monotherapy. However, high-quality RCTs are still needed to confirm the beneficial role of colistin-based combination therapy. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/myprospero, identifier CRD42025636727.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.